Molecular Partners AG
F:6ML0
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Molecular Partners AG
F:6ML0
|
CH |
|
P
|
Piche Resources Ltd
ASX:PR2
|
AU |
|
C
|
Catalano Seafood Ltd
ASX:CSF
|
AU |
|
G
|
Grupo International Inc
OTC:GRPI
|
US |
|
Integrated Business Systems and Services Inc
OTC:IBSS
|
US |
|
Zhende Medical Co Ltd
SSE:603301
|
CN |
|
P
|
Pelican Aqua Holding PLC
OSE:PLCAN
|
CY |
|
O
|
Oncodesign Precision Medicine SA
PAR:ALOPM
|
FR |
|
Burcon NutraScience Corp
OTC:BRCNF
|
CA |
|
F
|
Foran Mining Corp
F:48M
|
CA |
|
Cumulus Media Inc
F:1NM
|
US |
|
S
|
S G N Telecoms Ltd
BSE:531812
|
IN |
|
3
|
3S Korea Co Ltd
KOSDAQ:060310
|
KR |
|
M
|
Marblegate Acquisition Corp
NASDAQ:GATE
|
US |
|
D
|
Diversified Healthcare Trust
SWB:SNF
|
US |
|
F
|
Fancamp Exploration Ltd
XTSX:FNC
|
CA |
|
G
|
Gritstone bio Inc
SWB:2JQ
|
US |
|
P
|
Protect Pharmaceutical Corp
OTC:PRTT
|
US |
|
Ingen Technologies Inc
OTC:IGNT
|
US |
|
Renegade Gold Inc
F:0700
|
CA |
|
Sharing Services Global Corp
OTC:SHRG
|
US |
Bankruptcy Probability
Molecular Partners AG's probability of bankruptcy is Hidden . The solvency score is Hidden .
We take all the information about a company's solvency, such as how easily it can pay interest on outstanding debt, how much cash it has, the amount of debt, and more, and use it to estimate the probability of bankruptcy.
Solvency Ratios
Solvency Ratios Comparison
Molecular Partners AG Competitors
| Country | Company | Market Cap | D/E | D/A |
Interest Coverage |
Altman Z-Score |
Quick Ratio |
Current Ratio |
Cash Ratio |
||
|---|---|---|---|---|---|---|---|---|---|---|---|
| CH |
|
Molecular Partners AG
SIX:MOLN
|
126.4m CHF |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| JP |
|
Takara Bio Inc
TSE:4974
|
120.4T JPY |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
440.8B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
224.6B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
171.7B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
128.1B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
83.1B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
53.5B EUR |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
64.9B AUD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Molecular Partners AG's probability of bankruptcy is Hidden .
The probability of bankruptcy is estimated using credit risk models that assess financial health, debt levels, interest coverage, and other solvency indicators.
As of the latest report, Molecular Partners AG has total debt of 2.1m CHF. This includes both short-term (0 CHF) and long-term (2.1m CHF) debt.
You can find a full breakdown on its Balance Sheet.
